Total Payments
$198,658
2024 Payments
$72,942
Companies
24
Transactions
195
Medicare Patients
1,418
Medicare Billing
$374,359
Payment Breakdown by Category
Other$117,231 (59.0%)
Consulting$53,332 (26.8%)
Travel$23,248 (11.7%)
Food & Beverage$4,848 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $112,881 | 32 | 56.8% |
| Consulting Fee | $53,332 | 18 | 26.8% |
| Travel and Lodging | $23,248 | 84 | 11.7% |
| Food and Beverage | $4,848 | 60 | 2.4% |
| Honoraria | $4,350 | 1 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $63,402 | 47 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $34,715 | 50 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $23,496 | 18 | $0 (2024) |
| Helsinn Therapeutics (U.S.), Inc. | $22,893 | 21 | $0 (2022) |
| Daiichi Sankyo Inc. | $9,663 | 7 | $0 (2021) |
| EISAI INC. | $6,852 | 8 | $0 (2022) |
| ABBVIE INC. | $5,634 | 8 | $0 (2023) |
| Purdue Pharma L.P. | $4,603 | 2 | $0 (2017) |
| PFIZER INC. | $4,600 | 3 | $0 (2018) |
| JAZZ PHARMACEUTICALS INC. | $3,983 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $72,942 | 55 | Ipsen Biopharmaceuticals, Inc ($63,402) |
| 2023 | $4,572 | 2 | ABBVIE INC. ($4,572) |
| 2022 | $36,271 | 35 | Helsinn Therapeutics (U.S.), Inc. ($17,683) |
| 2021 | $23,241 | 17 | Daiichi Sankyo Inc. ($9,663) |
| 2020 | $3,761 | 6 | Genentech USA, Inc. ($1,650) |
| 2019 | $18,085 | 24 | Merck Sharp & Dohme Corporation ($13,157) |
| 2018 | $15,642 | 32 | Merck Sharp & Dohme Corporation ($6,460) |
| 2017 | $24,146 | 24 | Merck Sharp & Dohme Corporation ($12,623) |
All Payment Transactions
195 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,090.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| 11/19/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $401.00 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,525.00 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Travel and Lodging | In-kind items and services | $531.06 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Travel and Lodging | In-kind items and services | $373.36 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Travel and Lodging | In-kind items and services | $282.42 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Food and Beverage | In-kind items and services | $263.88 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,307.50 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $690.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $190.63 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $128.30 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $126.91 | General |
| Category: Oncology | ||||||
| 09/25/2024 | JAZZ PHARMACEUTICALS INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,982.50 | General |
| 09/18/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $41.80 | General |
| Category: NONE | ||||||
| 09/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,090.00 | General |
| Category: Oncology | ||||||
| 09/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Travel and Lodging | In-kind items and services | $507.94 | General |
| Category: Oncology | ||||||
| 09/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Travel and Lodging | In-kind items and services | $378.00 | General |
| Category: Oncology | ||||||
| 09/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Travel and Lodging | In-kind items and services | $244.93 | General |
| Category: Oncology | ||||||
| 09/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Food and Beverage | In-kind items and services | $232.19 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,655.00 | General |
| Category: Oncology | ||||||
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 05/30/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,480.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 373 | 933 | $584,860 | $92,619 |
| 2022 | 3 | 348 | 903 | $607,705 | $100,377 |
| 2021 | 5 | 385 | 1,142 | $693,058 | $111,475 |
| 2020 | 4 | 312 | 888 | $542,595 | $69,888 |
Total Patients
1,418
Total Services
3,866
Medicare Billing
$374,359
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 185 | 697 | $383,350 | $60,051 | 15.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 84 | 132 | $98,340 | $16,437 | 16.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 93 | 93 | $99,045 | $15,454 | 15.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 11 | $4,125 | $676.69 | 16.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 114 | 382 | $284,590 | $50,921 | 17.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 163 | 450 | $247,500 | $37,564 | 15.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 71 | 71 | $75,615 | $11,892 | 15.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 192 | 922 | $507,100 | $81,167 | 16.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 110 | 110 | $117,150 | $18,717 | 16.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 54 | 70 | $52,150 | $9,209 | 17.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 19 | $8,783 | $1,255 | 14.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 21 | $7,875 | $1,129 | 14.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 157 | 724 | $398,200 | $49,148 | 12.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 94 | 94 | $100,110 | $14,502 | 14.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 49 | 57 | $42,465 | $5,613 | 13.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 13 | $1,820 | $625.25 | 34.4% |
About Dr. Paul Oberstein, MD
Dr. Paul Oberstein, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/06/2008. The National Provider Identifier (NPI) number assigned to this provider is 1265686075.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Oberstein, MD has received a total of $198,658 in payments from pharmaceutical and medical device companies, with $72,942 received in 2024. These payments were reported across 195 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($112,881).
As a Medicare-enrolled provider, Oberstein has provided services to 1,418 Medicare beneficiaries, totaling 3,866 services with total Medicare billing of $374,359. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Medical Oncology
- Location New York, NY
- Active Since 11/06/2008
- Last Updated 06/14/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1265686075
Products in Payments
- Onivyde (Drug) $63,402
- TRUSELTIQ (Drug) $22,893
- LYNPARZA (Drug) $19,925
- Enhertu (Drug) $9,663
- Lenvima (Drug) $6,852
- SUTENT (Drug) $4,600
- CREON (Drug) $4,572
- THERASPHERE - BIO (Device) $3,533
- TECENTRIQ (Biological) $2,502
- RYBREVANT (Drug) $2,025
- ONIVYDE (Drug) $1,394
- Non-Covered Product (Drug) $1,064
- IMFINZI (Drug) $660.55
- XT CDX (Device) $41.80
- Xermelo (Drug) $19.27
- KEYTRUDA (Biological) $16.05
- OPDIVO (Biological) $15.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M